Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: beyond (184), exceeding (120)

Atezolizumab1680mg

Description: Chemotherapy Protocol LUNG CANCER Atezolizumab (1680mg 28 days) Regimen • Lung – Atezolizumab Indication • Ate
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab1680mg.pdf

Atezolizumab(1680-28days)

Description: Chemotherapy Protocol GENITOURINARY CANCER Atezolizumab (1680mg-28 days) Regimen • Urothelial– Atezolizumab (1
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab1680-28days.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description: Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

RFC PO (Lite) - Cyclophosphamide-Fludarabine- Rituximab PO (Lite) Ver 1.2

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE–FLUDARABINE–RITUXIMAB (RFC Oral Lite) Regimen Lymphoma – RFC PO (Lite) - Cycloph
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RFC-PO-Lite-Cyclophosphamide-Fludarabine-Rituximab-PO-Lite-Ver-1.2.pdf

InP- VTD-PACE (IV) Bortezomib (IV) Cisplatin Cyclophosphamide Dexamethasone Doxorubicin Etoposide Thalidomide

Description: Chemotherapy Protocol MULTIPLE MYELOMA VTD-PACE (IV)-BORTEZOMIB (IV)-CISPLATIN-CYCLOPHOSPHAMIDEDEXAMETHASONE-
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/InP-VTD-PACE-IV-Bortezomib-IV-Cisplatin-Cyclophosphamide-Dexamethasone-Doxorubicin-Etoposide-Thalidomide.pdf

InP- VTD PACE (SC) Bortezomib (SC) Cisplatin Cyclophosphamide Dexamethasone Doxorubicin Etoposide Thalidomide

Description: Chemotherapy Protocol MULTIPLE MYELOMA VTD-PACE (SC)-BORTEZOMIB (SC)-CISPLATIN-CYCLOPHOSPHAMIDEDEXAMETHASONE-
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/InP-VTD-PACE-SC-Bortezomib-SC-Cisplatin-Cyclophosphamide-Dexamethasone-Doxorubicin-Etoposide-Thalidomide.pdf

Ipilimumab-Nivolumab

Description: Chemotherapy Protocol SKIN CANCER IPILIMUMAB (3mg/kg)-NIVOLUMAB (1mg/kg) Regimen • Skin – Ipilimumab (3mg/k
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Ipilimumab-Nivolumab.pdf

Lenvatinib(60kg or greater)

Description: Chemotherapy Protocol HEPATOCELLULAR CANCER LENVATINIB (60kg or greater) Regimen • Hepatocellular – Lenvatinib Indication • Lenvatinib i
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Lenvatinib-60kg-or-greater-Ver1.pdf

Lenvatinib(59kg or less)

Description: Chemotherapy Protocol HEPATOCELLULAR CANCER LENVATINIB (59kg or less) Regimen • Hepatocellular – Lenvatinib Indication • Lenvatinib is i
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Lenvatinib-59kg-or-less-.pdf

Ipilimumab-Nivolumab Ver1

Description: Chemotherapy Protocol MESOTHELIOMA IPILIMUMAB-NIVOLUMAB Regimen • Mesothelioma – Ipilimumab-Nivolumab Indic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Mesothelioma/Ipilimumab-Nivolumab-Ver1.pdf

401 to 410 of 869

Previous … 39 40 41 42 43 … Next